Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

by Ysios Capital

4 years ago
LAVA-1223, growth factor receptor (EGFR), Seagen, EGFR+ tumor, Gammabody™

Seagen to Develop and Commercialize LAVA-1223, a Bispecific T Cell Engager Designed to Target and Activate Vγ9Vδ2 (Gamma Delta) T Cells in the Presence of EGFR-Expressing Solid Tumors

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

by Ysios Capital

4 years ago
SparingVision, SPVN06 and SPVN20, Retinitis Pigmentosa (RP)

SparingVision (“the Company”), a genomic medicine company developing vision-saving treatments for ocular diseases, today announces that it has raised €75 million in a Series B financing. The rou...

Xeltis receives commitment from Grand Pharma to invest €15M as cornerstone of ongoing Series D2 financing round

by Ysios Capital

4 years ago
Xeltis, Grand Pharma, hemodialysis, chronic kidney disease (CKD), Xeltis’ aXess device

Equity and licensing investment for aXess device marks first commercial deal

Study shows that selection of breast cancer patients for adjuvant bisphosphonate therapy based on Inbiomotion’s MAFTEST® reduces the risk of death in comparison with current clinical guidance

by Ysios Capital

4 years ago
Inbiomotion SL, MAFTEST®, MAF biomarker

Inbiomotion SL, a company developing a unique single-gene-based biomarker for the personalized adjuvant treatment of early-stage (stage I-III) breast cancer patients, announces the results of comparin...

Declaration of conformity drawn up for MAFTEST®

by Ysios Capital

4 years ago
medical device MAFTEST®, gen MAF

On 13 May 2022, the conformity assessment for the unique in vitro diagnostic medical device MAFTEST® developed by Inbiomotion was completed and the declaration of conformity was drawn up.

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AU-011) versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

by Ysios Capital

In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care.

Ysios Capital appoints Wen Wen Cheng as Head of Legal

by Ysios Capital

4 years ago
Wen Wen

Ysios Capital, a European life sciences venture capital firm, today announced that it has appointed Wen Wen Cheng as Head of Legal.

Mineralys Therapeutics Closes $118 Million Oversubscribed Series B Financing to Advance the Development of Novel, Targeted Treatment for Hypertension

by Ysios Capital

4 years ago
Ysios Capital, Mineralys Therapeutics

Mineralys plans to use the proceeds to continue to advance MLS-101, a highly selective aldosterone synthase inhibitor. MLS-101 is currently being evaluated in a Phase 2 clinical trial, called Target-H...

Minoryx raises €51 million in a round co-led by Columbus Venture Partners and Caixa Capital Risc to support Marketing Authorization Application and launch preparations for X-linked Adrenoleukodystrophy (X-ALD) therapy

by Ysios Capital

4 years ago
Fund+, Ysios Capital, Columbus Venture Partners, Caixa Capital Risc, Minoryx, Leriglitazone

The round was co-led by Columbus Venture Partners and Caixa Capital Risc. Dr. Damià Tormo, representing Columbus Venture Partners, has joined Minoryx’s Board of Directors. CDTI, through its Innvier...

Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal

by Ysios Capital

4 years ago
Ysios Capital

After a very active 2021, closing an oversubscribed €216M fund, 3 NASDAQ IPOs, and Sanifit’s landmark acquisition by Vifor Pharma, Ysios Capital is now focused on managing its portfolio companies ...

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

by Ysios Capital

4 years ago
SpliceBio, UCB Ventures, Ysios Capital, New Enterprise Associates, Gilde Healthcare, Novartis Venture Fund, Asabys Partners

SpliceBio, a biotechnology company exploiting protein splicing to develop next generation gene therapies, today announced the completion of an oversubscribed €50 million series A financing. The fina...

NorthSea Therapeutics, supported by Ysios Capital, Initiates Phase 1 Trial of SEFA-6179, Targeting the Orphan Indication Intestinal Failure-Associated Liver Disease

by Ysios Capital

4 years ago
NorthSea Therapeutics, Ysios Capital

NorthSea Therapeutics B.V., (‘NST’), a biotech company developing novel and innovative strategies for the treatment of NASH and other metabolic diseases, announces it has initiated a Phase 1 stud...